ruxolitinib and decitabine in patients with post-mpn aml
Published 4 years ago • 47 plays • Length 4:48Download video MP4
Download video MP3
Similar videos
-
1:55
ruxolitinib plus decitabine in post-mpn aml
-
1:38
the search for better post-mpn aml treatment: decitabine and ruxolitinib
-
2:51
ruxolitinib in combination with abemaciclib for patients with primary or post-pv/et myelofibrosis
-
1:21
ruxolitinib plus venetoclax in heavily pretreated patients with r/r aml
-
1:51
treatment schedule for ruxolitinib in patients with mpns and how to assess response
-
5:19
cramer: this biotech stock could be worth over $100 billion on an fda approval
-
7:43
exploring a therapy called jakafi® (ruxolitinib)
-
6:44
how does jakafi® (ruxolitinib) work?
-
2:11
the management of post-mpn aml
-
2:11
update on phase i/ii study of azacitidine, venetoclax and gilteritinib in patients with flt3 aml
-
1:03
10-day astx727 (decitabine/cedazuridine) with venetoclax in the treatment of r/r aml
-
1:27
insights into the reveal trial: the efficacy of ruxolitinib for the treatment of patients with pv
-
2:39
a phase ii trial of ruxolitinib and azacitidine combination therapy in patients with myelofibrosis
-
1:20
the impact of early ruxolitinib treatment on os in the comfort-i and comfort-ii studies
-
1:38
pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
1:46
tagraxofusp combined with azacitidine and venetoclax in the treatment of bpdcn and aml
-
3:56
an update on manifest: pelabresib monotherapy or as add-on to ruxolitinib in myelofibrosis
-
1:27
quizartinib, venetoclax, and decitabine in patients with flt3-itd aml: a phase i/ii trial
-
1:30
the use of pirtobrutinib in richter's transformation: data from the bruin trial
-
1:46
ruxolitinib in 2024 and beyond: the good, the suboptimal, and the failure
-
1:16
the rationale for combining magrolimab with ruxolitinib in myelofibrosis